聯交所譴責優通未來(06168.HK) 上市委員會施加制裁
聯交所對清盤中的優通未來(06168.HK)採取紀律行動,指出該公司在被提出數宗清盤呈請時沒有通知聯交所及刊發公告,以及延遲刊發財務報告,至今仍未刊發其2020財政年度的年度業績及送交其2020財政年度的年度報告。
上市委員會裁定優通未來違反《上市規則》第13.25(1)(b)條及第 13.49(1)及13.46(2)(a)條,決定施加制裁,聯交所確認制裁僅適用於該公司,而不適用於該公司任何過往或現任董事會成員。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.